A novel LARCassigner3 classification predicts outcomes in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: a retrospective training and validation analysis

References

• Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–1933. doi:10.1200/JCO.2011.40.183622529255
   PubMed Web of Science ®Google Scholar
• Bosset J, Calais G, Mineur L, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results–EORTC 22921. J Clin Oncol. 2005;23(24):5620–5627. doi:10.1200/JCO.2005.02.11316009958
   PubMed Web of Science ®Google Scholar
• Bosset J, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–1123. doi:10.1056/NEJMoa06082916971718
   PubMed Web of Science ®Google Scholar
• Guillem J, Chessin D, Cohen A, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241(5):829–36; discussion 36–8.
   PubMed Web of Science ®Google Scholar
• Fokas E, Liersch T, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014;32(15):1554–1562. doi:10.1200/JCO.2013.54.376924752056
   PubMed Web of Science ®Google Scholar
• Huebner M, Wolff B, Smyrk T, Aakre J, Larson D. Partial pathologic response and nodal status as most significant prognostic factors for advanced rectal cancer treated with preoperative chemoradiotherapy. World J Surg. 2012;36(3):675–683. doi:10.1007/s00268-011-1409-822270980
   PubMed Web of Science ®Google Scholar
• Nacion A, Park Y, Kim N. Contemporary management of locally advanced rectal cancer: resolving issues, controversies and shifting paradigms. Chin J Cancer Res. 2018;30(1):131–146. doi:10.21147/j.issn.1000-9604.2018.01.1429545727
   PubMed Web of Science ®Google Scholar
• Roselló S, Papaccio F, Roda D, Tarazona N, Cervantes A. The role of chemotherapy in localized and locally advanced rectal cancer: a systematic revision. Cancer Treat Rev. 2018;63:156–171. doi:10.1016/j.ctrv.2018.01.00129407455
   PubMed Web of Science ®Google Scholar
• Wu A, Cai Y, Li Y, et al. Pattern and management of recurrence of mid-low rectal cancer after neoadjuvant intensity-modulated radiotherapy: single-center results of 687 cases. Clin Colorectal Cancer. 2018;17:e307–e313. doi:10.1016/j.clcc.2018.01.00629525524
   PubMed Web of Science ®Google Scholar
• Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–3734. doi:10.1200/JCO.2005.04.798516720680
   PubMed Web of Science ®Google Scholar
• Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10(4):R65. doi:10.1186/bcr212418662380
   PubMed Web of Science ®Google Scholar
• Sparano J, Gray R, Makower D, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111–121. doi:10.1056/NEJMoa180471029860917
   PubMed Web of Science ®Google Scholar
• De Sousa E, Melo F, Wang X, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013;19(5):614–618. doi:10.1038/nm.317423584090
   PubMed Web of Science ®Google Scholar
• Sadanandam A, Lyssiotis C, Homicsko K, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19(5):619–625. doi:10.1038/nm.317523584089
   PubMed Web of Science ®Google Scholar
• Roepman P, Schlicker A, Tabernero J, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer. 2014;134(3):552–562. doi:10.1002/ijc.2838723852808
   PubMed Web of Science ®Google Scholar
• Song N, Pogue-Geile K, Gavin P, et al. Clinical outcome from oxaliplatin treatment in stage II/III colon cancer according to intrinsic subtypes: secondary analysis of NSABP C-07/NRG oncology randomized clinical trial. JAMA Oncol. 2016;2(9):1162–1169. doi:10.1001/jamaoncol.2016.231427270348
   PubMed Web of Science ®Google Scholar
• Dunne P, McArt D, Bradley C, et al. Challenging the cancer molecular stratification dogma: intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer. Clin Cancer Res. 2016;22(16):4095–4104. doi:10.1158/1078-0432.CCR-16-003227151745
   PubMed Web of Science ®Google Scholar
• Trinh A, Trumpi K, De Sousa E, et al. Practical and robust identification of molecular subtypes in colorectal cancer by immunohistochemistry. Clin Cancer Res. 2017;23(2):387–398. doi:10.1158/1078-0432.CCR-16-068027459899
   PubMed Web of Science ®Google Scholar
• Trumpi K, Ubink I, Trinh A, et al. Neoadjuvant chemotherapy affects molecular classification of colorectal tumors. Oncogenesis. 2017;6(7):e357. doi:10.1038/oncsis.2017.4828692036
   PubMedGoogle Scholar
• Reed S, Dinan M, Schulman K, Lyman G. Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genet Med. 2013;15(3):203–211. doi:10.1038/gim.2012.11922975761
   PubMed Web of Science ®Google Scholar
• Zhang X, Song Y, Lu H, et al. Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas. World J Gastroenterol. 2015;21(9):2629–2637. doi:10.3748/wjg.v21.i9.262925759530
   PubMed Web of Science ®Google Scholar
• Bagci B, Sari M, Karadayi K, Turan M, Ozdemir O, Bagci G. KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients. Cancer Biomark. 2016;17(2):133–143. doi:10.3233/CBM-16062427540971
   PubMed Web of Science ®Google Scholar
• Veeck J, Noetzel E, Bektas N, et al. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer. Mol Cancer. 2008;7:83. doi:10.1186/1476-4598-7-8318990230
   PubMed Web of Science ®Google Scholar
• Chen L, Jiang B, Zhong C, et al. Chemoprevention of colorectal cancer by black raspberry anthocyanins involved the modulation of gut microbiota and SFRP2 demethylation. Carcinogenesis. 2018;39(3):471–481. doi:10.1093/carcin/bgy00929361151
   PubMed Web of Science ®Google Scholar
• Mirotsou M, Zhang Z, Deb A, et al. Secreted frizzled related protein 2 (SFRP2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci USA. 2007;104(5):1643–1648. doi:10.1073/pnas.061002410417251350
   PubMed Web of Science ®Google Scholar
• Morath I, Hartmann T, Orian-Rousseau V. CD44: more than a mere stem cell marker. Int J Biochem Cell Biol. 2016;81(Pt A):166–173. doi:10.1016/j.biocel.2016.09.00927640754
   PubMedGoogle Scholar
• Mueller N, Wicklein D, Eisenwort G, et al. CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. Blood. 2018;132:1936–1950. doi:10.1182/blood-2018-02-83358230018080
   PubMed Web of Science ®Google Scholar
• Hertenstein A, Schumacher T, Litzenburger U, et al. Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10. Biochem Pharmacol. 2011;82(6):632–641. doi:10.1016/j.bcp.2011.06.01321703247
   PubMed Web of Science ®Google Scholar
• Ruehlmann JM, Xiang R, Niethammer AG, et al. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res. 2001;61(23):8498–8503. 11731434
   PubMed Web of Science ®Google Scholar
• Zhang R, Tian L, Chen LJ, et al. Combination of MIG (CXCL9) chemokine gene therapy with low-dose Cisplatin improves therapeutic efficacy against murine carcinoma. Gene Ther. 2006;13(17):1263–1271. doi:10.1038/sj.gt.330275616672984
   PubMed Web of Science ®Google Scholar
• Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev. 2006;25(3):357–371. doi:10.1007/s10555-006-9003-517016763
   PubMed Web of Science ®Google Scholar
• Li G, Tian L, Hou JM, et al. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors. Clin Cancer Res. 2005;11(11):4217–4224. doi:10.1158/1078-0432.CCR-04-211715930360
   PubMed Web of Science ®Google Scholar
• Jiang Z, Xu Y, Cai S. CXCL10 expression and prognostic significance in stage II and III colorectal cancer. Mol Biol Rep. 2010;37(6):3029–3036. doi:10.1007/s11033-009-9873-z19821051
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Charoentong P, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2010;138(4):1429–1440. doi:10.1053/j.gastro.2009.10.05719909745
   PubMed Web of Science ®Google Scholar
• Frederick MJ, Clayman GL. Chemokines in cancer. Expert Rev Mol Med. 2001;3(19):1–18. doi:10.1017/S1462399401003301
   PubMedGoogle Scholar
• Kawada K, Sonoshita M, Sakashita H, et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res. 2004;64(11):4010–4017. doi:10.1158/0008-5472.CAN-03-175715173015
   PubMed Web of Science ®Google Scholar
• Buess M, Terracciano L, Reuter J, et al. STRAP is a strong predictive marker of adjuvant chemotherapy benefit in colorectal cancer. Neoplasia (New York, NY). 2004;6(6):813–820. doi:10.1593/neo.04307
   PubMed Web of Science ®Google Scholar
• Aguilera O, Muñoz A, Esteller M, Fraga MF. Epigenetic alterations of the Wnt/beta-catenin pathway in human disease. Endocr Metab Immune Disord Drug Targets. 2007;7(1):13–21. doi:10.2174/18715300778005945017346200
   PubMedGoogle Scholar
• Caldwell GM, Jones CE, Taniere P, et al. The WNT antagonist SFRP1 is downregulated in premalignant large bowel adenomas. Br J Cancer. 2006;94(6):922–927. doi:10.1038/sj.bjc.660296716523202
   PubMed Web of Science ®Google Scholar
• Zhao LH, Lin QL, Wei J, Huai YL, Wang KJ, Yan HY. CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression. Int J Clin Exp Pathol. 2015;8(1):692–701. 25755763
   PubMed Web of Science ®Google Scholar
• Zlobec I, Terracciano L, Tornillo L, et al. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer. Gut. 2008;57(10):1413–1419. doi:10.1136/gut.2007.14119218436576
   PubMed Web of Science ®Google Scholar
• Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis. 2013;28(1):9–18. doi:10.1007/s00384-012-1520-922733437
   PubMed Web of Science ®Google Scholar
• Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–1356. doi:10.1038/nm.396726457759
   PubMed Web of Science ®Google Scholar
• Wielenga VJ, Smits R, Korinek V, et al. Expression of CD44 in APC and TCF mutant mice implies regulation by the WNT pathway. Am J Pathol. 1999;154(2):515–523. doi:10.1016/S0002-9440(10)65297-210027409
   PubMed Web of Science ®Google Scholar
• Todaro M, Gaggianesi M, Catalano V, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014;14(3):342–356. doi:10.1016/j.stem.2014.01.00924607406
   PubMed Web of Science ®Google Scholar
• Li XD, Ji M, Wu J, Jiang JT, Wu CP. Clinical significance of CD44 variants expression in colorectal cancer. Tumori. 2013;99(1):88–92. doi:10.1700/1248.1379423549006
   PubMed Web of Science ®Google Scholar
• Ghadimi BM, Grade M, Difilippantonio MJ, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol. 2005;23(9):1826–1838. doi:10.1200/JCO.2005.00.40615774776
   PubMed Web of Science ®Google Scholar
• Watanabe T, Komuro Y, Kiyomatsu T, et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res. 2006;66(7):3370–3374. doi:10.1158/0008-5472.CAN-05-383416585155
   PubMed Web of Science ®Google Scholar
• Hur H, Tulina I, Cho MS, et al. Biomarker-based scoring system for prediction of tumor response after preoperative chemoradiotherapy in rectal cancer by reverse transcriptase polymerase chain reaction analysis. Dis Colon Rectum. 2016;59(12):1174–1182. doi:10.1097/DCR.000000000000071127824703
   PubMed Web of Science ®Google Scholar
• Lal N, White BS, Goussous G, et al. KRAS mutation and consensus molecular subtypes 2 and 3 are independently associated with reduced immune infiltration and reactivity in colorectal cancer. Clin Cancer Res. 2018;24(1):224–233. doi:10.1158/1078-0432.CCR-17-109029061646
   PubMedGoogle Scholar
• Isella C, Brundu F, Bellomo S, et al. Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. Nat Commun. 2017;8:15107. doi:10.1038/ncomms1510728561063
   PubMed Web of Science ®Google Scholar
• Karpinski P, Rossowska J, Sasiadek M. Immunological landscape of consensus clusters in colorectal cancer. Oncotarget. 2017;8(62):105299–105311. doi:10.18632/oncotarget.2216929285252
   PubMedGoogle Scholar
• Sveen A, Bruun J, Eide P, et al. Colorectal cancer consensus molecular subtypes translated to preclinical models uncover potentially targetable cancer cell dependencies. Clin Cancer Res. 2018;24(4):794–806. doi:10.1158/1078-0432.CCR-17-123429242316
   PubMed Web of Science ®Google Scholar
• Alderdice M, Richman S, Gollins S, et al. Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies. J Pathol. 2018. doi:10.1002/path.5051
   PubMed Web of Science ®Google Scholar
• Maas M, Beets-Tan R, Lambregts D, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633–4640. doi:10.1200/JCO.2011.37.717622067400
   PubMed Web of Science ®Google Scholar
• Rullier E, Rouanet P, Tuech J, et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet. 2017;390(10093):469–479. doi:10.1016/S0140-6736(17)31056-528601342
   PubMed Web of Science ®Google Scholar